A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2245 participants.

Also called NCT01195662

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,245 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01195662
  • EudraCT 2010-019798-13
Other papers using this trial's data
  • Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study The lancet. Diabetes & endocrinology, 2016-03 DOI, PubMed 26620248 PubMed links an erratum for this paper. Erratum: PMID 29471920

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Colombia, Czechia, Denmark, Finland, Germany, Hungary, India, Ireland, Mexico, Poland, Puerto Rico, Romania, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01195662. Randomized; triple masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2014-05-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo matching Dapagliflozin
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct01195662
Content hash
af680eccdffec1f5c68afc37597a97bd87b65c12607aab942242aa77b4bb5d27